This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342(17):1255–65.
Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood 2017;129(6):667–79.
Fisher DAC, Malkova O, Engle EK, Miner CA, Fulbright MC, Behbehani GK, et al. Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia. Leukemia 2017;31(9):1962–74.
Cervantes F, Pereira A. Does ruxolitinib prolong the survival of patients with myelofibrosis? Blood 2017;129(7):832–7.
Barosi G, Rosti V, Gale RP. Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis. Onco Targets Ther. 2015;8:1091–102.
Venugopal S, Mascarenhas J. Current clinical investigations in myelofibrosis. Hematol Oncol Clin North Am. 2021;35(2):353–73.
Newberry KJ, Patel K, Masarova L, Luthra R, Manshouri T, Jabbour E, et al. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood 2017;130(9):1125–31.
Mascarenhas J, Mehra M, He J, Potluri R, Loefgren C. Patient characteristics and outcomes after ruxolitinib discontinuation in patients with myelofibrosis. J Med Econ. 2020;23(7):721–7.
Kuykendall AT, Shah S, Talati C, Al Ali N, Sweet K, Padron E, et al. Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. Ann Hematol. 2018;97(3):435–41.
Pemmaraju N, Garcia JS, Potluri J, Holes L, Harb J, Jung P, et al. The addition of navitoclax to ruxolitinib demonstrates efficacy within different high-risk populations in patients with relapsed/refractory myelofibrosis. Blood. 2020;136:39–40.
Yacoub A, Wang E, Rampal R, Borate U, Kremyanskaya M, Ali H, et al. Addition of parsaclisib (INCB050465), a PI3K delta inhibitor, in patients with suboptimal response to ruxolitinib: a phase 2 study in patients with myelofibrosis. Br J Haematol. 2021;193:9.
Pettit K, Gerds AT, Yacoub A, Watts JM, Tartaczuch M, Bradley TJ, et al. A phase 2a study of the LSD1 inhibitor Img-7289 (bomedemstat) for the treatment of myelofibrosis. Blood. 2019;134:556.
Mascarenhas J, Komrokji RS, Cavo M, Martino B, Niederwieser D, Reiter A, et al. Potential disease-modifying activity of imetelstat demonstrated by reduction in cytogenetically abnormal clones and mutation burden leads to clinical benefits in relapsed/refractory myelofibrosis patients. Blood. 2020;136:39–40.
Sanchez R, Zhou MM. The role of human bromodomains in chromatin biology and gene transcription. Curr Opin Drug Discov Dev. 2009;12(5):659–65.
Shi J, Vakoc CR. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol Cell. 2014;54(5):728–36.
Kleppe M, Koche R, Zou L, van Galen P, Hill CE, Dong L, et al. Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms. Cancer Cell. 2018;33(4):785–7.
Fiskus W, Cai TY, DiNardo CD, Kornblau SM, Borthakur G, Kadia TM, et al. Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Blood Cancer J. 2019;9:1–13.
Albrecht BK, Gehling VS, Hewitt MC, Vaswani RG, Cote A, Leblanc Y, et al. Identification of a benzoisoxazoloazepine inhibitor (CPI-0610) of the bromodomain and extra-terminal (BET) family as a candidate for human clinical trials. J Med Chem. 2016;59(4):1330–9.
Somervaille T, Verstovsek S, Mascarenhas J, Kremyanskaya M, Hoffman R, Rampal R, et al. CPI-0610, bromodomain and extraterminal domain protein (BET) inhibitor, as “add-on” to ruxolitinib, in advanced myelofibrosis patients with suboptimal response: update of MANIFEST phase 2 study. Br J Haematol. 2021;193:98–9.
Mead A, Mascarenhas J, Talpaz M, Patriarca A, Devos T, Palandri F, et al. CPI-0610, a bromodomain and extraterminal domain protein (bet) inhibitor, in combination with ruxolitinib, in jak-inhibitor-naive myelofibrosis patients: update of manifest phase 2 study. Br J Haematol. 2021;193:96-.
Verstovsek S, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Kadia T, et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 2012;120(6):1202–9.
JM, AG, and SV conceived the work that led to the submission, drafted the paper, approved the final version, and agreed to be accountable for all aspects of the work.
JM has received research support paid to his institution from PharmaEssentia, Abbvie, CTI Bio, Merck, Roche, Novartis, BMS, Forbius, Kartos, Incyte, Geron, Sierra Oncology; consulting or advisory board fees from Kartos, CTI Bio, Constellation, Incyte, Roche, Novartis, BMS, Abbvie, PharmaEssentia, and Geron. AG has received advisory board fees from PharmaEssentia, BMS, Novartis, AbbVie, Sierra Oncology. SV has received research support paid to his institution from Incyte, Roche, NS Pharma, Celgene, Gilead, Promedior, CTI BioPharma, Blueprint Medicines Corp., Novartis, Sierra Oncology, PharmaEssentia, Constellation, Protagonist, Kartos; advisory board fees from Constellation, BMS, Sierra Oncology, Incyte, Novartis, Celgene, PharmaEssentia.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Mascarenhas, J., Gerds, A. & Verstovsek, S. Paradigm shift: combination BET and JAK inhibition in myelofibrosis. Leukemia 35, 3361–3363 (2021). https://doi.org/10.1038/s41375-021-01405-z
This article is cited by
New Treatments for Myelofibrosis
Current Treatment Options in Oncology (2023)